{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:21:31Z","timestamp":1793740891231,"version":"4.6.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>De novo purine biosynthesis (DNPS) was previously shown to be aberrantly activated in many cancers. However, the activity of DNPS pathway and its underlying regulatory mechanism in hepatoblastoma (HB) remain poorly understood. Herein, we discovered that the expression of PPAT, the rate-limiting enzyme in DNPS, was markedly upregulated in HB, leading to an augmented purine flux via DNPS, thereby promoting both HB cell proliferation and migration. Furthermore, we found that activated mutant \u03b2-catenin, a dominant driver of HB, transcriptionally activated <jats:italic>PPAT<\/jats:italic> expression, hence stimulating DNPS and constituting a druggable metabolic vulnerability in HB. Consistently, pharmacological targeting using a DNPS inhibitor lometrexol or genetic repressing the enhanced DNPS markedly blocked HB progression in vitro and in vivo. Our findings suggest that HB patients harboring activated \u03b2-catenin mutations and consequent DNPS upregulation, may be treated efficaciously with DNPS enzyme inhibitors like lometrexol. These novel findings bear major therapeutic implications for targeted precision medicine of HB.<\/jats:p>","DOI":"10.1038\/s41419-025-07502-6","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:38:21Z","timestamp":1742218701000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Therapeutic targeting de novo purine biosynthesis driven by \u03b2-catenin-dependent PPAT upregulation in hepatoblastoma"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0661-7928","authenticated-orcid":false,"given":"Ming","family":"Ding","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunshuang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houshun","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiquan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongxiang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhua","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yabin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-392X","authenticated-orcid":false,"given":"Liang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6692-8221","authenticated-orcid":false,"given":"Yehuda G.","family":"Assaraf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8819-5719","authenticated-orcid":false,"given":"Bin-Bing S.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6568-1623","authenticated-orcid":false,"given":"Song","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-694X","authenticated-orcid":false,"given":"Hui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"7502_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/jncics\/pkz007","volume":"3","author":"AK Hubbard","year":"2019","unstructured":"Hubbard AK, Spector LG, Fortuna G, Marcotte EL, Poynter JN. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988-2012. JNCI Cancer Spectr. 2019;3:pkz007.","journal-title":"JNCI Cancer Spectr"},{"key":"7502_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1053\/j.semdp.2016.12.015","volume":"34","author":"D Sharma","year":"2017","unstructured":"Sharma D, Subbarao G, Saxena R. Hepatoblastoma. Semin Diagn Pathol. 2017;34:192\u2013200.","journal-title":"Semin Diagn Pathol"},{"key":"7502_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29763","volume":"69","author":"JA Kahla","year":"2022","unstructured":"Kahla JA, Siegel DA, Dai S, Lupo PJ, Foster JH, Scheurer ME, et al. Incidence and 5-year survival of children and adolescents with hepatoblastoma in the United States. Pediatr Blood Cancer. 2022;69:e29763.","journal-title":"Pediatr Blood Cancer"},{"key":"7502_CR4","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","volume":"18","author":"RL Meyers","year":"2017","unstructured":"Meyers RL, Maibach R, Hiyama E, Haberle B, Krailo M, Rangaswami A, et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children\u2019s Hepatic tumors International Collaboration. Lancet Oncol. 2017;18:122\u201331.","journal-title":"Lancet Oncol"},{"key":"7502_CR5","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/pbc.22088","volume":"53","author":"RL Meyers","year":"2009","unstructured":"Meyers RL, Rowland JR, Krailo M, Chen Z, Katzenstein HM, Malogolowkin MH. Predictive power of pretreatment prognostic factors in children with hepatoblastoma: a report from the Children\u2019s Oncology Group. Pediatr Blood Cancer. 2009;53:1016\u201322.","journal-title":"Pediatr Blood Cancer"},{"key":"7502_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/HMER.S89997","volume":"9","author":"AD Trobaugh-Lotrario","year":"2017","unstructured":"Trobaugh-Lotrario AD, Meyers RL, O\u2019Neill AF, Feusner JH. Unresectable hepatoblastoma: current perspectives. Hepat Med. 2017;9:1\u20136.","journal-title":"Hepat Med"},{"key":"7502_CR7","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1055\/s-0040-1722645","volume":"41","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Solinas A, Cairo S, Evert M, Chen X, Calvisi DF. Molecular mechanisms of hepatoblastoma. Semin Liver Dis. 2021;41:28\u201341.","journal-title":"Semin Liver Dis"},{"key":"7502_CR8","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/hep.28888","volume":"65","author":"P Sumazin","year":"2017","unstructured":"Sumazin P, Chen Y, Trevino LR, Sarabia SF, Hampton OA, Patel K, et al. Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups. Hepatology. 2017;65:104\u201321.","journal-title":"Hepatology"},{"key":"7502_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41575-018-0075-9","volume":"16","author":"MJ Perugorria","year":"2019","unstructured":"Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, et al. Wnt-beta-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16:121\u201336.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"7502_CR10","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Martinez-Reyes","year":"2021","unstructured":"Martinez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"7502_CR11","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1158\/2159-8290.CD-21-1059","volume":"12","author":"D Hanahan","year":"2022","unstructured":"Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31\u201346.","journal-title":"Cancer Discov"},{"key":"7502_CR12","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1093\/nar\/gkv047","volume":"43","author":"AN Lane","year":"2015","unstructured":"Lane AN, Fan TWM. Regulation of mammalian nucleotide metabolism and biosynthesis. Nucleic Acids Res. 2015;43:2466\u201385.","journal-title":"Nucleic Acids Res"},{"key":"7502_CR13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.drup.2012.07.002","volume":"15","author":"N Gonen","year":"2012","unstructured":"Gonen N, Assaraf YG. Antifolates in cancer therapy: structure, activity and mechanisms of drug resistance. Drug Resist Updat. 2012;15:183\u2013210.","journal-title":"Drug Resist Updat"},{"key":"7502_CR14","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.drup.2016.06.004","volume":"28","author":"S Raz","year":"2016","unstructured":"Raz S, Stark M, Assaraf YG. Folylpoly-gamma-glutamate synthetase: a key determinant of folate homeostasis and antifolate resistance in cancer. Drug Resist Updat. 2016;28:43\u201364.","journal-title":"Drug Resist Updat"},{"key":"7502_CR15","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.1002\/hep4.1559","volume":"4","author":"YC Chong","year":"2020","unstructured":"Chong YC, Toh TB, Chan Z, Lin QXX, Thng DKH, Hooi L, et al. Targeted inhibition of purine metabolism is effective in suppressing hepatocellular carcinoma progression. Hepatol Commun. 2020;4:1362\u201381.","journal-title":"Hepatol Commun"},{"key":"7502_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17512-x","volume":"11","author":"W Zhou","year":"2020","unstructured":"Zhou W, Yao Y, Scott AJ, Wilder-Romans K, Dresser JJ, Werner CK, et al. Purine metabolism regulates DNA repair and therapy resistance in glioblastoma. Nat Commun. 2020;11:3811.","journal-title":"Nat Commun"},{"key":"7502_CR17","doi-asserted-by":"crossref","unstructured":"Zhao Z, Cao K, Watanabe J, Philips CN, Zeidner JM, Ishi Y, et al. Therapeutic targeting of metabolic vulnerabilities in cancers with MLL3\/4-COMPASS epigenetic regulator mutations. J Clin Invest. 2023;133:e169993.","DOI":"10.1172\/JCI169993"},{"key":"7502_CR18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202157119","volume":"119","author":"F Liu","year":"2022","unstructured":"Liu F, Gai X, Wu Y, Zhang B, Wu X, Cheng R, et al. Oncogenic beta-catenin stimulation of AKT2-CAD-mediated pyrimidine synthesis is targetable vulnerability in liver cancer. Proc Natl Acad Sci USA. 2022;119:e2202157119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7502_CR19","doi-asserted-by":"crossref","unstructured":"Agarwal S, Chakravarthi BVSK, Behring M, Kim H-G, Chandrashekar DS, Gupta N, et al. PAICS, a purine nucleotide metabolic enzyme, is involved in tumor growth and the metastasis of colorectal cancer. Cancers. 2020;12:772.","DOI":"10.3390\/cancers12040772"},{"key":"7502_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15136-9","volume":"11","author":"M Kodama","year":"2020","unstructured":"Kodama M, Oshikawa K, Shimizu H, Yoshioka S, Takahashi M, Izumi Y, et al. A shift in glutamine nitrogen metabolism contributes to the malignant progression of cancer. Nat Commun. 2020;11:1320.","journal-title":"Nat Commun"},{"key":"7502_CR21","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add3685","volume":"9","author":"D Hany","year":"2023","unstructured":"Hany D, Vafeiadou V, Picard D. CRISPR-Cas9 screen reveals a role of purine synthesis for estrogen receptor alpha activity and tamoxifen resistance of breast cancer cells. Sci Adv. 2023;9:eadd3685.","journal-title":"Sci Adv"},{"key":"7502_CR22","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.aad0489","volume":"351","author":"I Ben-Sahra","year":"2016","unstructured":"Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728\u201333.","journal-title":"Science"},{"key":"7502_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/nn.4537","volume":"20","author":"X Wang","year":"2017","unstructured":"Wang X, Yang K, Xie Q, Wu Q, Mack SC, Shi Y, et al. Purine synthesis promotes maintenance of brain tumor initiating cells in glioma. Nat Neurosci. 2017;20:661\u201373.","journal-title":"Nat Neurosci"},{"key":"7502_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1038\/s41375-021-01369-0","volume":"36","author":"T Yamauchi","year":"2022","unstructured":"Yamauchi T, Miyawaki K, Semba Y, Takahashi M, Izumi Y, Nogami J, et al. Targeting leukemia-specific dependence on the de novo purine synthesis pathway. Leukemia. 2022;36:383\u201393.","journal-title":"Leukemia"},{"key":"7502_CR25","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1038\/s41556-022-00965-1","volume":"24","author":"FF Diehl","year":"2022","unstructured":"Diehl FF, Miettinen TP, Elbashir R, Nabel CS, Darnell AM, Do BT, et al. Nucleotide imbalance decouples cell growth from cell proliferation. Nat Cell Biol. 2022;24:1252\u201364.","journal-title":"Nat Cell Biol"},{"key":"7502_CR26","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.cell.2011.03.044","volume":"145","author":"AC Bester","year":"2011","unstructured":"Bester AC, Roniger M, Oren YS, Im MM, Sarni D, Chaoat M, et al. Nucleotide deficiency promotes genomic instability in early stages of cancer development. Cell. 2011;145:435\u201346.","journal-title":"Cell"},{"key":"7502_CR27","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1119-7","volume":"18","author":"L Liu","year":"2019","unstructured":"Liu L, Wang J, Sun G, Wu Q, Ma J, Zhang X, et al. m(6)A mRNA methylation regulates CTNNB1 to promote the proliferation of hepatoblastoma. Mol Cancer. 2019;18:188.","journal-title":"Mol Cancer"},{"key":"7502_CR28","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.tcb.2023.03.003","volume":"33","author":"ES Ali","year":"2023","unstructured":"Ali ES, Ben-Sahra I. Regulation of nucleotide metabolism in cancers and immune disorders. Trends Cell Biol. 2023;33:950\u201366.","journal-title":"Trends Cell Biol"},{"key":"7502_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-2033-z","volume":"10","author":"CHY Cheung","year":"2019","unstructured":"Cheung CHY, Hsu C-L, Tsuei C-Y, Kuo T-T, Huang C-T, Hsu W-M, et al. Combinatorial targeting of MTHFD2 and PAICS in purine synthesis as a novel therapeutic strategy. Cell Death Dis. 2019;10:786.","journal-title":"Cell Death Dis"},{"key":"7502_CR30","doi-asserted-by":"crossref","unstructured":"Villa E, Ali ES, Sahu U, Ben-Sahra I. Cancer cells tune the signaling pathways to empower de novo synthesis of nucleotides. Cancers. 2019;11:688.","DOI":"10.3390\/cancers11050688"},{"key":"7502_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.483","volume":"5","author":"Y Li","year":"2024","unstructured":"Li Y, Zhu L, Mao J, Zheng H, Hu Z, Yang S, et al. Genome-scale CRISPR-Cas9 screen identifies PAICS as a therapeutic target for EGFR wild-type non-small cell lung cancer. MedComm. 2024;5:e483.","journal-title":"MedComm"},{"key":"7502_CR32","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1158\/1535-7163.MCT-23-0550","volume":"23","author":"A Wallace-Povirk","year":"2024","unstructured":"Wallace-Povirk A, O\u2019Connor C, Dekhne AS, Bao X, Nayeen MJ, Schneider M, et al. Mitochondrial and cytosolic one-carbon metabolism is a targetable metabolic vulnerability in cisplatin-resistant ovarian cancer. Mol Cancer Ther. 2024;23:809\u201322.","journal-title":"Mol Cancer Ther"},{"key":"7502_CR33","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1158\/2767-9764.CRC-23-0450","volume":"4","author":"NK Tangudu","year":"2024","unstructured":"Tangudu NK, Buj R, Wang H, Wang J, Cole AR, Uboveja A, et al. De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression. Cancer Res Commun. 2024;4:1174\u201388.","journal-title":"Cancer Res Commun"},{"key":"7502_CR34","doi-asserted-by":"publisher","first-page":"e2722","DOI":"10.1371\/journal.pone.0002722","volume":"3","author":"Y-C Liu","year":"2008","unstructured":"Liu Y-C, Li F, Handler J, Huang CRL, Xiang Y, Neretti N, et al. Global regulation of nucleotide biosynthetic genes by c-Myc. PLoS ONE. 2008;3:e2722.","journal-title":"PLoS ONE"},{"key":"7502_CR35","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/nar\/gkn910","volume":"37","author":"PM Wilson","year":"2009","unstructured":"Wilson PM, Fazzone W, LaBonte MJ, Lenz H-J, Ladner RD. Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage. Nucleic Acids Res. 2009;37:78\u201395.","journal-title":"Nucleic Acids Res"},{"key":"7502_CR36","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajpath.2016.09.022","volume":"187","author":"K Holzer","year":"2017","unstructured":"Holzer K, Drucker E, Roessler S, Dauch D, Heinzmann F, Waldburger N, et al. Proteomic analysis reveals GMP synthetase as p53 repression target in liver cancer. Am J Pathol. 2017;187:228\u201335.","journal-title":"Am J Pathol"},{"key":"7502_CR37","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.bbrc.2012.01.077","volume":"418","author":"H-R Kim","year":"2012","unstructured":"Kim H-R, Roe J-S, Lee J-E, Hwang I-Y, Cho E-J, Youn H-D. A p53-inducible microRNA-34a downregulates Ras signaling by targeting IMPDH. Biochem Biophys Res Commun. 2012;418:682\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"7502_CR38","doi-asserted-by":"crossref","unstructured":"Li G, Wu J, Li L, Jiang P. p53 deficiency induces MTHFD2 transcription to promote cell proliferation and restrain DNA damage. Proc Natl Acad Sci USA. 2021;118:e2019822118.","DOI":"10.1073\/pnas.2019822118"},{"key":"7502_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05625-2","volume":"14","author":"J Zhao","year":"2023","unstructured":"Zhao J, Zhou X, Chen B, Lu M, Wang G, Elumalai N, et al. p53 promotes peroxisomal fatty acid beta-oxidation to repress purine biosynthesis and mediate tumor suppression. Cell Death Dis. 2023;14:87.","journal-title":"Cell Death Dis"},{"key":"7502_CR40","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1016\/j.molcel.2020.05.001","volume":"78","author":"ES Ali","year":"2020","unstructured":"Ali ES, Sahu U, Villa E, O\u2019Hara BP, Gao P, Beaudet C, et al. ERK2 phosphorylates PFAS to mediate posttranslational control of de novo purine synthesis. Mol Cell. 2020;78:1178\u201391.e1176.","journal-title":"Mol Cell"},{"key":"7502_CR41","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1021\/acs.jproteome.8b00969","volume":"18","author":"C Liu","year":"2019","unstructured":"Liu C, Knudsen GM, Pedley AM, He J, Johnson JL, Yaron TM, et al. Mapping post-translational modifications of de novo purine biosynthetic enzymes: Implications for pathway regulation. J Proteome Res. 2019;18:2078\u201387.","journal-title":"J Proteome Res"},{"key":"7502_CR42","doi-asserted-by":"publisher","first-page":"5423","DOI":"10.1038\/sj.onc.1202918","volume":"18","author":"M Ruas","year":"1999","unstructured":"Ruas M, Brookes S, McDonald NQ, Peters G. Functional evaluation of tumour-specific variants of p16INK4a\/CDKN2A: correlation with protein structure information. Oncogene. 1999;18:5423\u201334.","journal-title":"Oncogene"},{"key":"7502_CR43","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1158\/0008-5472.CAN-07-1528","volume":"67","author":"R Jones","year":"2007","unstructured":"Jones R, Ruas M, Gregory F, Moulin S, Delia D, Manoukian S, et al. A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. Cancer Res. 2007;67:9134\u201341.","journal-title":"Cancer Res"},{"key":"7502_CR44","doi-asserted-by":"publisher","first-page":"17524","DOI":"10.1074\/jbc.RA119.009979","volume":"294","author":"W Zhang","year":"2019","unstructured":"Zhang W, Meyfeldt J, Wang H, Kulkarni S, Lu J, Mandel JA, et al. beta-Catenin mutations as determinants of hepatoblastoma phenotypes in mice. J Biol Chem. 2019;294:17524\u201342.","journal-title":"J Biol Chem"},{"key":"7502_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jcmgh.2021.02.004","volume":"12","author":"H Wang","year":"2021","unstructured":"Wang H, Lu J, Mandel JA, Zhang W, Schwalbe M, Gorka J, et al. Patient-derived mutant forms of NFE2L2\/NRF2 drive aggressive murine hepatoblastomas. Cell Mol Gastroenterol Hepatol. 2021;12:199\u2013228.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"7502_CR46","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1126\/science.1152241","volume":"320","author":"S An","year":"2008","unstructured":"An S, Kumar R, Sheets ED, Benkovic SJ. Reversible compartmentalization of de novo purine biosynthetic complexes in living cells. Science. 2008;320:103\u20136.","journal-title":"Science"},{"key":"7502_CR47","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1073\/pnas.1423009112","volume":"112","author":"CY Chan","year":"2015","unstructured":"Chan CY, Zhao H, Pugh RJ, Pedley AM, French J, Jones SA, et al. Purinosome formation as a function of the cell cycle. Proc Natl Acad Sci USA. 2015;112:1368\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7502_CR48","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/nchembio.690","volume":"7","author":"F Verrier","year":"2011","unstructured":"Verrier F, An S, Ferrie AM, Sun H, Kyoung M, Deng H, et al. GPCRs regulate the assembly of a multienzyme complex for purine biosynthesis. Nat Chem Biol. 2011;7:909\u201315.","journal-title":"Nat Chem Biol"},{"key":"7502_CR49","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1073\/pnas.1300173110","volume":"110","author":"JB French","year":"2013","unstructured":"French JB, Zhao H, An S, Niessen S, Deng Y, Cravatt BF, et al. Hsp70\/Hsp90 chaperone machinery is involved in the assembly of the purinosome. Proc Natl Acad Sci USA. 2013;110:2528\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"7502_CR50","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1126\/science.aac6054","volume":"351","author":"JB French","year":"2016","unstructured":"French JB, Jones SA, Deng H, Pedley AM, Kim D, Chan CY, et al. Spatial colocalization and functional link of purinosomes with mitochondria. Science. 2016;351:733\u20137.","journal-title":"Science"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07502-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07502-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T14:00:19Z","timestamp":1742220019000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07502-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7502"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07502-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The patient sample harvests in this study were conducted in accordance with both the Declarations of Helsinki and Istanbul. They were evaluated and approved by the Institutional Review Board of Shanghai Children\u2019s Medical Center (SCMC, Permit No. SCMCIRB-K2022098-1). All the patients have signed informed consent. The animal experiments in this study were followed ARRIVE guidelines. They were evaluated and approved by the Institutional Animal Care and Use Committee (IACUC) of SCMC (Permit No. SCMC-LAWEC-2022-041).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"179"}}